Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Dejardin · SciRah

Researcher profile · Semantic Scholar

D. Dejardin

Share profile

D. Dejardin — researcher profile on SciRah

h-index: 16
Works: 48
Citations: 920

Most-cited papers

Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily
H. Kantarjian, R. Pasquini, V. Lévy, S. Jootar +7 more
2009Cancer223 citations Open access
Semantic Scholar
Including historical data in the analysis of clinical trials: Is it worth the effort?
J. van Rosmalen, D. Dejardin, Y. van Norden, B. Lowenberg +1 more
2017Statistical Methods in Medical Research142 citations Open access
Semantic Scholar
Modified power prior with multiple historical trials for binary endpoints
Akalu Banbeta, J. van Rosmalen, D. Dejardin, E. Lesaffre
2018Statistics in Medicine56 citations Open access
Semantic Scholar
Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.
A. Hochhaus, Neil P. Shah, J. Cortes, M. Baccarani +3 more
201241 citations
Semantic Scholar
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
W. V. So, D. Dejardin, E. Rossmann, J. Charo
2023Journal for ImmunoTherapy of Cancer40 citations Open access
Semantic Scholar
Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
N. Shah, H. Kantarjian, Dong-Wook Kim, A. Hochhaus +8 more
201138 citations
Semantic Scholar
A multistate model for early decision‐making in oncology
U. Beyer, D. Dejardin, M. Meller, K. Rufibach +1 more
2018Biometrical journal. Biometrische Zeitschrift29 citations Open access
Semantic Scholar
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
N. Steeghs, C. Gomez-Roca, K. Rohrberg, M. Mau-Sørensen +15 more
2024Clinical Cancer Research26 citations Open access
Semantic Scholar
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects
D. Dejardin, P. Delmar, Charles Warne, Katie Patel +2 more
2018Pharmaceutical statistics23 citations
Semantic Scholar
Joint modeling of progression‐free survival and death in advanced cancer clinical trials
D. Dejardin, E. Lesaffre, G. Verbeke
2010Statistics in Medicine23 citations
Semantic Scholar
Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
A. Italiano, L. Verlingue, H. Prenen, E. Guerra +16 more
202120 citations
Semantic Scholar
Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.
H. J. Khoury, J. Cortes, H. Kantarjian, M. Baccarani +4 more
201019 citations
Semantic Scholar
Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R
P. Rousselot, T. Facon, R. Paquette, E. Bleickardt +2 more
200819 citations
Semantic Scholar
Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).
H. Kantarjian, P. Rousselot, R. Pasquini, N. Hamerschlak +4 more
200719 citations
Semantic Scholar
Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial.
N. Shah, P. Rousselot, R. Pasquini, N. Hamerschlak +4 more
2006Journal of Clinical Oncology19 citations
Semantic Scholar
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
L. Verlingue, A. Italiano, H. Prenen, E. G. Guerra Alía +28 more
2024EBioMedicine17 citations Open access
Semantic Scholar
Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib
C. Schiffer, J. Cortes, G. Saglio, P. le Coutre +4 more
201016 citations
Semantic Scholar
Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.
N. Shah, R. Pasquini, P. Rousselot, S. Jootar +5 more
200614 citations
Semantic Scholar
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
H. Prenen, S. Deva, B. Keam, Colin R Lindsay +25 more
2024Clinical Cancer Research13 citations Open access
Semantic Scholar
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
S. Peters, E. Angevin, T. Alonso-Gordoa, K. Rohrberg +21 more
2024Clinical Cancer Research12 citations
Semantic Scholar
Stochastic EM algorithm for doubly interval-censored data.
D. Dejardin, E. Lesaffre
2013Biostatistics11 citations
Semantic Scholar
Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
J. Pérez-Gracia, A. Hansen, R. Eefsen, C. Gomez-Roca +16 more
202110 citations
Semantic Scholar
A composite decision rule of CD8+ T cell density in tumor biopsies predicts efficacy in early-stage, immunotherapy trials.
D. Dejardin, A. Kraxner, Annika Blank, N. Rieder +5 more
2023Clinical Cancer Research9 citations
Semantic Scholar
Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial
G. Saglio, A. Hochhaus, J. Cortes, H. Kantarjian +4 more
20109 citations
Semantic Scholar
Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors
T. Yap, Natalie Cook, Elisa Fontana, Erica S. Tsang +24 more
2025Cancer Research8 citations
Semantic Scholar
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R. Hansen, C. Gomez-Roca, D. Robbrecht, L. Verlingue +20 more
2024Clinical Cancer Research8 citations Open access
Semantic Scholar
Association of lymphocytosis following treatment with dasatinib with response and outcome.
Celia A. Schiffer, J. Cortes, G. Saglio, P. le Coutre +3 more
20108 citations
Semantic Scholar
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
E. Muñoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long +23 more
2025Cancer Research Communications7 citations Open access
Semantic Scholar
A randomized phase I Bayesian dose escalation design for the combination of anti‐cancer drugs
D. Dejardin, E. Lesaffre, P. Hamberg, J. Verweij
2014Pharmaceutical statistics7 citations
Semantic Scholar
Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial
F. Guilhot, H. Kantarjian, N. Shah, A. Hochhaus +3 more
20107 citations
Semantic Scholar
An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies
D. Dejardin, A. Kraxner, Emilie Schindler, Nicolas Städler +1 more
2024Frontiers in Immunology6 citations Open access
Semantic Scholar
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
D. Dejardin, Bo Huang, Ying Yuan, Ulrich Beyer +2 more
2024Statistics in Biopharmaceutical Research5 citations
Semantic Scholar
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.
M. Vieito, Elisa Fontana, Catherine H. Han, Eduardo Castañón +23 more
2026Journal of Clinical Oncology4 citations
Semantic Scholar
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.
T. Yap, Elisa Fontana, N. Cook, M. Fakih +36 more
2026Nature Medicine3 citations Open access
Semantic Scholar
Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Elisa Fontana, María Vieito Villar, Eduardo Castañón Álvarez, Ignacio Matos +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
A. Hansen, C. Gomez-Roca, M. Lolkema, L. Verlingue +15 more
2021Annals of Oncology2 citations Open access
Semantic Scholar
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
J. Pérez-Gracia, B. Mellado, Aaron R. Hansen, T. Alonso-Gordoa +34 more
2026Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
I. Melero, N. Steeghs, U. Lassen, K. Homicsko +13 more
2026Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Bayesian analysis of restricted mean survival time adjusted for covariates using pseudo-observations
L'ea Orsini Cesp, U, Emmanuel Lesaffre, Guosheng Yin +4 more
20251 citations
Semantic Scholar
Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
M. Vieito, Elisa Fontana, Catherine H. Han, Eduardo Castañón +20 more
2025Cancer Research1 citations
Semantic Scholar
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
I. Melero, J. Tabernero, N. Steeghs, D. Robbrecht +21 more
2025Clinical Cancer Research1 citations Open access
Semantic Scholar
Bayesian generalized method of moments applied to pseudo-observations in survival analysis
Léa Orsini, C. Brard, Emmanuel Lesaffre, Guosheng Yin +2 more
2024Lifetime Data Analysis1 citations Open access
Semantic Scholar
Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.
M. Vieito, Elisa Fontana, G. Schnetzler, D. Dejardin +3 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
126P Results of first-in-human (FiH) study of mosperafenib in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC)
E. Fontana, C. Han, E. Álvarez, D. Pinato +16 more
2026Annals of Oncology0 citations Open access
Semantic Scholar
822P Evaluating ctDNA as a predictive biomarker in a phase I clinical trial of mosperafenib in BRAFV600E-mutant colorectal cancer
O. Bechter, M. L. Serrano Serano, C. Sie, M. Vieito +16 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
Abstract 5464: Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data
W. So, D. Dejardin, E. Rossmann, J. Charo
2023Cancer Research0 citations
Semantic Scholar
Dose Ranging Studies and Dose Determination
P. Woodward, A. Bedding, D. Dejardin
20200 citations
Semantic Scholar
Statistical Models for the Analysis of Oncology Endpoints
D. Dejardin
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Keshelava×13
Invite
N. Keshelava — researcher profile on SciRah
J. Charo×12
Invite
J. Charo — researcher profile on SciRah
C. Boetsch×11
Invite
C. Boetsch — researcher profile on SciRah
H. Prenen×11
Invite
H. Prenen — researcher profile on SciRah

×10

Invite

A. Kraxner — researcher profile on SciRah

Invite

N. Shah — researcher profile on SciRah

Stefan Evers×9

Invite

Stefan Evers — researcher profile on SciRah

H. Kantarjian×8

Invite

H. Kantarjian — researcher profile on SciRah

Invite

J. Cortes — researcher profile on SciRah

Volker Teichgräber×7

Invite

Volker Teichgräber — researcher profile on SciRah

Invite

E. Lesaffre — researcher profile on SciRah

Nassim Sleiman×6

Invite

Nassim Sleiman — researcher profile on SciRah